

Grab a blank piece of paper and a pen ... we are drawing a penguin ... 2 minutes





Annotate as we go along – or use chat

Top, Bottom or Middle of page



o chat

Annotate as we go along – or use chat Left, Right or Front of facing

Annotate as we go along – or use chat

• Lots of details or Few details

Annotate as we go along – or use chat

Wings close to body or outstretched


Annotate as we go along – or use chat

Big beak vs big feet





Hospital Onset Bacteremia



Disclosures

Tricia Cooper, BScN, RN

Employee of Medline Industries






Objectives

- Understand the origins and impact of HOB
- Detail why HOB as a quality Measure
- Identify sources for infection not reportable but causing sepsis
- Discuss the costs and prevention of HOB

Post-Pandemic: 2022 – Today







Moving Towards HOB

Hospital Onset Bacteremia (HOB)

The growth of recognized bacterial or fungal pathogen from blood culture specimen Obtained ≥ Day 3 of admission^{1,8}


Annotate or Chat



1. My facility is: (pick no more than 2) Please select at most 2 options. Tracking HAI's Tracking HOB Talking about HOB None of the above All of the above

Origins of HOB





Procedures

microbiome

Why HOB as a Quality Measure?



- Broader Focus and Evidence
- Straightforward Methodology to collect data
- Clinically impactful to patients and systems across all care
- Objective / measurable
- All patient areas to be included
- Prevalence- One study found a median rate of HOB at 0.124/100 admissions¹

HOB: By the Numbers







Estimated at least

4x higher than CLABSI rates




HOB events have a **3x** higher mortality rate in patients with ICU stay, a higher risk of readmission, higher costs, and significantly longer LOS



#1 Cause of HOB Respiratory

HOB as a Reportable Measure





- Intended to be fully automated
- Reduced surveillance burden for IP
- Based on standards, measurement science, and clinical science
- Collected on all positive blood cultures
- Manual reporting will not be an option

Testing Sites from CMS CoLab Group



Site	Site Name	EHR Vendor*	Measures	Site Leads
1	Billings Clinic	Oracle/Cerner	Glycemic Control	Randy Thompson, MD Lisa Ranes, RD, LN, CDCES
2	Geisinger	Epic	CDI/HOB, RPS	Mark Shelly, MD
3	HCA Healthcare	Meditech, Allscripts, Oracle/Cerner	CDI/HOB, Glycemic Control	Kenneth Sands, MD, MPH William Gregg, MD, MS, MPH
4	Mass General Brigham	Epic	Sepsis	Sayon Dutta, MD, MPH Chanu Rhee, MD, MPH
5	Michigan Medicine	Epic	Glycemic Control, CDI/HOB, HA-VTE	Michael Lanham, MD
6	Nebraska Medicine	Epic	Glycemic Control	Andjela Drincic, MD Ron Carson
7	University of California, Davis Medical Center	Epic	Glycemic Control	Greg Maynard, MD, MS, MHM Yauheni Solad, MD, MHS, MBA
8	University of North Carolina Hospitals	Epic	CDI/HOB, RPS	Lisa Stancill, MPH
9	University of Oklahoma Health Sciences Center	Epic	HA-VTE	Aaron Wendelboe, PhD Justin Dvorak, PhD
10	University of Rochester Medical Center	Epic	CDI/HOB	Brenda Tesini, MD
11	Yale New Haven Health	Epic	Glycemic Control	Nitu Kashyap, MD, FAMIA Hyung Paek, MD, MSEE

Annotate or Chat



- 2. Our biggest infection concern is: (pick one)
- 1 Central lines
- 2 PIV's
- 3 Arterial lines
- 4 Surgical Infections
- 5 CAUTI
- **6** Respiratory
- **7** None of the above



2024 IPPS Rules: Open Comments on HOB and Fungemia



What We Assume:

Voluntary for at last 2 cycles
Baseline data benchmarks established
Data collection for potential penalty phase



What We Need Answered:

How will other measures be looked at How will workflows be changed How will staff be burdened

What is being missed?



Adult Sepsis Event = Presumed Serious Infection + Acute Organ Dysfunction (eSOFA)

HO-ASE+/NHSN HAI-

1967 cases (0.7% of hospitalizations)

533 deaths (28.1% mortality)

HO-ASE

2301 cases (0.8% of hospitalizations)

657 deaths (28.9% mortality)

Reportable NHSN HAI

1260 cases (0.4% of hospitalizations)

162 deaths (12.9% mortality)

NHSN HAI+/HO-ASE-

926 cases (0.3% of hospitalizations)

58 deaths (6.3% mortality)

Overlap HO-ASE/ NHSN HAI

334 cases (0.1% of hospitalizations)

104 deaths (31.1% mortality)





110 of the HO-ASEs manually chart reviewed found that current surveillance for HAIs required for reporting to NHSN detected only 15% of Hospital Onset ASE, and that mortality rates associated far exceeded those for HAIs.

This finding supports recent data showing the majority of Hospital Onset Bacteremia cases are **NOT** associated with an **HAI** that is currently reported to **NHSN**.

Non-ventilator HAP was one of the most common causes.

Infectious Syndrome	No. of Cases of Infection (%)
Pneumonia	43 (39.1)
Ventilator-associated pneumonia	15 (13.6)
Urinary tract infection	8 (7.3)
Catheter-associated urinary tract infection	7 (6.4)
Bloodstream infection	19 (17.3)
Central line-associated	2 (1.8)
Non-central line endovascular source	3 (2.7)
Oral/gastrointestinal source	6 (5.5)
Urogential source	1 (0.9)
Skin source	1 (0.9)
Unknown source	6 (5.5)
Clostridiodes difficile	3 (2.7)
Intra-abdominal infection (other than C. difficile)	16 (14.5)
Skin and soft tissue infection	7 (6.4)
Pleural space/intrathoracic infection	2 (1.8)
Obstetric/gynecologic source	1 (0.9)
Febrile neutropenia without clear source	15 (13.6)
Unknown source	10 (9.1)

HOB: The Next Frontier in Hospital Acquired Infections Identifying HOB







GI-ABD Endocarditis






Medically Complex Increased LOS Increased Mortality

Identifying HOB




HOB demographics information	N (%)
Average Charlson comorbidity index	4.97
Average age	56
Average LOS (days)	29.23
Died/In-hospital mortality	93 (23.7%)
Average BMI	29.3 (9.2)
ID consult obtained	233 (59.4%)
Transferred from OSH	165 (42.0%)
CVC POA	106 (27.0%)
NHSN-reported CLABSIs	59 (15.0%)
Arterial Line Present	65 (16.6%)
Foley present	110 (28.0%)
1 PIV present	264 (67.3%)
2 PIV present	171 (43.6%)
3 PIV present	74 (18.9%)
4 PIV present	24 (6.1%)



Preventable HOB







1. 3.3% Misc or unknown cause

Addressing Hospital Onset Bacteremia












Changes in Infection Preventionist World

- Once Primarily nurses and usually with a good bit of bedside experience
 - o One study shows over an 8% drop in nursing discipline for IPs from 2017 to 2020.
 - o Post Covid large % of nursing IP experience retired or left the profession.
- Microbiology professionals made up the bulk of alternative disciplines becoming IPs
- Introduction of MPH as IP specialists.
- How does this impact clinical practice support? Improvement in data driven measures but what does this mean for application clinically at the bedside?



Prevention is the Best Intervention



Definition of a Bundle – IHI

A <u>small set</u> of <u>evidence-based</u>
<u>interventions</u> for a <u>defined patient</u>
<u>segment/population</u> and <u>care setting</u> that,
when <u>implemented together</u>, will result in significantly
<u>better outcomes</u> than when implemented individually.



Bundles



Bundles are supported and recommended in most clinical standards and guidelines:


- INS, SHEA, ONS, APIC and CDC
- Small, straightforward interventions
- 3-5 interventions at most
- Creates consistency



How can we make it easy to do the right thing every time?

Cost Impact and Prevention





Reimbursement + Penalties + Lost Cost to Treat

Resources required to prevent HAIs/HACs

- People
- Process
- Products

Are we doing enough BEFORE the measure goes into effect?

Pre-Assessment for HOB Practices



HOB Source	Current Processes	Opportunities to Develop	Priority Level



Retrospectively review your data

- 21 % choose RIJ Primary and Femoral Secondary
- Half that use Femoral as Primary Residents
- Arterial lines 61% sutured + 22% CDI
- CHG scrub
 - 47% motion
 - 25% moist time
 - 87% dry time
- 36% IJ sites CDI
- CVAD + PIV 40.3% of PIVs were in use
- 50% of PIVs not in use had 0 CVAD lumens in use
 - 9% of CVADs were not CDL



^{*}CDI= Clean, Dry and Intact



Where are the opportunities

Device & Site Selection
Algorithm

Inserter Training

Arterial Securement

PIV utilization

Following IFU

Blood Culture Stewardship

Final Thoughts





- HOB is the future of outcomes surveillance and P4P metrics
- Preparation is key to mitigate the impact
- Proactive tools and resources will reduce operational costs
- Collaboration internally and with healthcare industry partners is key

Sources



- 1. Yu, Kalvin, et. al; Infection Control & Hospital Epidemiology. Hospital-onset bacteremia and fungemia: An evaluation of predictors and feasibility of benchmarking comparing two risk-adjusted models among 267 hospitals. (2022) 43; 1317-1325.
- 2. Federal Register Vol. 88 No 165/ Monday, August 28, 2023/Rules and Regulations pg 59109-59114.
- 3. Page, B., Klompas, M. et.al; Clinical Infectious Diseases. Surveillance for Healthcare-Associated Infections: Hospital-Onset Adult Sepsis Events Versus Current Reportable Conditions. (2021) 73 15 September; 1013-1019.
- 4. Garcia, R.; Journal of Infusion Nursing. Moving Beyond Central Line-Associated Bloodstream Infections: Enhancement of the Prevention Process. July/Aug 2023. Vol 46: No 4, pg 217-222
- 5. Dantes, R., Abbo, L. Et.al; Infection Control Hosp Epidemiology. Hospital Epidemiologists' and infection preventionists' opinions regarding hospital-onset bacteremia and fungemia as a potential healthcare-associated infection metric. 2019- May; 40(5); 536-540.
- 6. AHRQ Paper. Estimated the Additional Hospital Inpatient Cost and Mortality Associated with Selected Hospital-Acquired Conditions. Created November 2017. www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/pfp/hac-cost-report2017.pdf
- 7. Haque, M. McKimm, J. et. Al; Risk Management and Healthcare Policy. Strategies to Prevent Healthcare-Associated Infections: A Narrative Overview. 2020:13 1765-1780.
- 8. Stack, M. Dbeibo, L., Et. al.; American Journal of Infection Control. Etiology and Utility of Hospital-Onset Bacteremia as a Safety Metric for Targeted Harm Reduction. (2024) 52; 195-199.